AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02325284 — intervention group
Intervention type: DEVICE
Intervention: Pressure Algometer Testing
Study NCT01741675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire and monetary incentive
Study NCT01741675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire only
Study NCT01934686 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study NCT00116350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800 mcg sublingual misoprostol
Study NCT00116350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IU Oxytocin IV
Study NCT00432614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR58611A
Description: oral administration
Study NCT00432614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: oral administration
Study NCT00432614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral administration
Study NCT00432614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT02883023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrosclerotherapy
Description: Combination of intralesional bleomycin sclerotherapy and electroporation
Study NCT02883023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional bleomycin injection
Description: Local intralesional injections with bleomycin
Study NCT02122198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
Study NCT02122198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Climara transdermal patch 0.075mg/day applied weekly months 6-9
Study NCT02122198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone
Description: Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
Study NCT02122198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00005039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-prostate specific antigen vaccine
Description: Given IM
Study NCT00005039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia prostate-specific antigen vaccine
Description: Given intradermally
Study NCT00005039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04050982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AF CARE
Description: Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
Study NCT04050982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AF CARE
Description: Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
Study NCT04050982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
Study NCT02170402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa (recombinant human coagulation factor VIII)
Description: * Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~* Part 2: On-demand treatment regimen~* Part 3: Prophylaxis treatment regimen
Study NCT02164695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPCI plus RIPC
Description: All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
Study NCT02164695 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PPCI only
Description: All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
Study NCT03412656 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SoftHand Pro with CUFF force feedback device
Description: Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
Study NCT03412656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoftHand Pro with CUFF force feedback device
Description: Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
Study NCT03040375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer counselling
Study NCT01332357 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate/salmeterol combination ED MD
Description: Receipt of fluticasone propionate/salmeterol combination from the ED physician
Study NCT01332357 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate/salmeterol combination OP MD
Description: Receipt of fluticasone propionate/salmeterol combination from the OP physician
Study NCT01260012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Praziquantel+antioxidant suppl
Description: Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
Study NCT01260012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel + placebo 2mths then antioxidant for 10 mths
Description: Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
Study NCT01260012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Praziquantel therapy and placebo as supplement
Description: Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
Study NCT01260012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Praziquantel+antioxidant
Description: Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
Study NCT05149898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002
Description: CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh > 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD.
Study NCT01514487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
Study NCT03516526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Natalizumab
Description: Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
Study NCT02034942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-sedation
Study NCT02034942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation, control
Study NCT01720342 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic Valve Replacement surgery
Description: Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
Study NCT03388359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial challenge with allergen
Description: Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
Study NCT03388359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial challenge with allergen
Description: Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
Study NCT03388359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-culture formation
Description: Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
Study NCT03388359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Co-culture formation
Description: Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
Study NCT03388359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhibition of Wnt and Smad signaling pathways
Description: Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
Study NCT03388359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhibition of Wnt and Smad signaling pathways
Description: Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
Study NCT03388359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracellular matrix turnover and deposition assessment
Description: Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
Study NCT03388359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracellular matrix turnover and deposition assessment
Description: Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermatophagoides pteronyssinus allergen
Description: Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dermatophagoides pteronyssinus allergen
Description: Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
Study NCT03388359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dosimeter ProvoX (Ganshorn)
Description: Device for allergen bronchial challenge test.
Study NCT03378986 — intervention group
Intervention type: PROCEDURE
Intervention: Unilateral total hip arthroplasty
Description: Replacement of one hip joint through a mininvasive surgical procedure
Study NCT03378986 — intervention group
Intervention type: PROCEDURE
Intervention: Simultaneous bilateral total hip arthroplasty
Description: Replacement of both hip joints through one-stage mininvasive surgical procedure
Study NCT03388359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dosimeter ProvoX (Ganshorn)
Description: Device for allergen bronchial challenge test.
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eosinophils
Description: Eosinophils are isolated from peripheral blood
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eosinophils
Description: Eosinophils are isolated from peripheral blood
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Airway smooth muscle cells
Description: Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Airway smooth muscle cells
Description: Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblasts
Description: Normal human fibroblast cell lines (commercial fibroblast lines)
Study NCT03388359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibroblasts
Description: Normal human fibroblast cell lines (commercial fibroblast lines)
Study NCT04203732 — intervention group
Intervention type: PROCEDURE
Intervention: Anesthesia Type
Description: The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
Study NCT00822731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without radiotherapy
Description: Treatment regimen will be determined by the sub-type of lymphoma
Study NCT00933179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
Study NCT00933179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE/Levonorgestrel (Microgynon, BAY86-4977)
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
Study NCT04671277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing of breads
Description: During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container.
Study NCT03193697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cemented SPII prosthesis
Description: Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
Study NCT03193697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cementless Wagner prosthesis
Description: Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
Study NCT00748280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-visit root canal therapy
Description: Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
Study NCT00748280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
Study NCT01295528 — intervention group
Intervention type: DEVICE
Intervention: Comparison test
Description: Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
Study NCT03731650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus lift
Description: non grafted maxillary sinus floor augmentation with simultaneous implant placement
Study NCT01316861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Acarbose
Description: EMS Acarbose 50 mg 3 times a day
Study NCT01316861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bayer Acarbose
Description: Bayer Acarbose 50 mg 3 times a day
Study NCT01810185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose naltrexone
Description: 4.5 mg daily for 12 weeeks
Study NCT01810185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03592706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IKC (Immune Killer Cells)
Study NCT03592706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE (Transcatheter Arterial Chemoembolization)
Study NCT03592706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE (Transcatheter Arterial Chemoembolization)
Study NCT03688880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAR-CUTIS
Description: MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds >8 cm, 2 syringes were required.
Study NCT03688880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Advanced
Description: Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
Study NCT01183559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vandetanib
Description: Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
Study NCT01183559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5 Fluorouracil (FU)
Description: 5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
Study NCT01183559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC=5 days 1 and 29 during radiation therapy
Study NCT01183559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
Study NCT01183559 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy (RT)
Description: External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
Study NCT00635037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and acupuncture
Description: * trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week
Study NCT04720235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lucira COVID-19 All-In-One test kit
Description: The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider